The Joint Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JYNT research report →
Range $20 – $20
Price Chart
About the company
The Joint Corp. specializes in the establishment, proprietorship, operation, and overall administration of chiropractic treatment centers. Its business operations are structured into two main divisions: corporate-owned clinics and franchised facilities.
- CEO
- Sanjiv Razdan
- IPO
- 2014
- Employees
- 330
- HQ
- Scottsdale, AZ, US
Get TickerSpark's AI analysis on JYNT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $84.74M
- P/E
- 31.01
- Fwd P/E
- 25.44
- PEG
- 0.07
- P/S
- 1.44
- P/B
- 7.09
- EV/EBITDA
- 14.21
- Div Yield
- 0.00%
- Gross Margin
- 81.57%
- Op Margin
- 4.43%
- Net Margin
- 4.81%
- ROE
- 19.28%
- ROIC
- 10.61%
Latest fiscal year · YoY change
- Revenue
- $54.90M+5.2%
- Gross Profit
- $43.67M+7.4%
- Op Income
- $-905,478
- Net Income
- $2.91M+150.2%
- EPS
- $0.19+148.7%
- OCF Growth
- -80.5%
- FCF Growth
- -95.9%
- 52W High
- $10.67
- 52W Low
- $6.19
- 50D MA
- $7.35
- 200D MA
- $8.36
- Beta
- 1.16
- RSI (14)
- 32
- Avg Volume
- 79.45K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
The Joint delivered modest revenue growth and sharply better profitability in Q3, but weaker consumer spending still pressured comps and led management to trim full-year sales expectations.· November 5, 2026
- Revenue rose 1% year over year to $13.6 million, while adjusted EBITDA from continuing operations increased to $2.3 million from $1.4 million.
- Comp sales improved sequentially to -1.9% from -2.8% in Q2, but remained negative as consumer spending stayed weak.
- Active membership, retention, and patient lifetime value improved, helped by flexible membership plans and win-back efforts.
- The company continued its shift to a capital-light franchisor model, with 15 remaining company-owned or managed clinics still in transfer.
- Full-year 2026 outlook was cut for system-wide sales, while adjusted EBITDA guidance of $12.5 million to $13.5 million was reiterated.
Third-quarter revenue increased 1% year over year to $13.6 million. System-wide sales were $123 million, down 3.1% year over year, and comp sales were -1.9% versus -2.8% in Q2 and -4.2% in Q1. Net income from continuing operations rose to $1.5 million from $290 thousand a year ago, and adjusted EBITDA from continuing operations increased to $2.3 million from $1.4 million. Consolidated adjusted EBITDA was $3.3 million, in line with Q3 2025. Unrestricted cash ended the quarter at $18.3 million, operating cash flow was negative $128 thousand, and free cash flow was negative $509 thousand. For full-year 2026, management now expects system-wide sales of $508 million to $512 million and comp sales of -3.5% to -2.5%, while reiterating consolidated adjusted EBITDA guidance of $12.5 million to $13.5 million. The company also expects year-end clinic count to be approximately 50 units below year-end 2025.
Sanjiv Razdan said the quarter showed that efforts to strengthen patient engagement and reshape the operating model are starting to work together. He emphasized improving membership, retention, and lifetime value, while acknowledging that the consumer environment is still weighing on new patient volume and average spend per month. His tone was constructive but cautious, with a clear message that the company’s priority for 2027 is to improve comp sales.
Scott Baumann focused on the improving economics of the franchisor model and the balance sheet. He cited royalty fees up 2% to $8.3 million, G&A down 6% to $6.9 million, and adjusted EBITDA from continuing operations up to $2.3 million. He also highlighted $18.3 million of unrestricted cash, an undrawn $20 million credit facility available through August 2029, and $8 million paid after quarter-end to reacquire Texas RD rights. Capital allocation remains split between growth investment, RD buybacks, and share repurchases; the company bought back about 461 thousand shares for $3.8 million in Q3 and received a new $5 million authorization after completing the prior $12 million program.
Analysts focused on why newer franchise clinics are performing better, whether the clinic-count reduction is mostly done, and whether flexible memberships are driving incremental demand or just offsetting attrition. Management said newer clinics are benefiting from tougher site selection, stronger operators, and stricter preopening compliance, with recent 2026 openings reaching breakeven in about 3 months versus about 18 months historically. On memberships, Sanjiv said the new plans are helping both conversion and retention, but they also diluted average spend by about $2 per patient per month in the near term. On the comp decline, management pointed to macro pressure such as inflation and gas prices, along with lower average spend, rather than a single operational issue.
The bull case is that the business is showing better underlying membership dynamics even while comps remain negative: active members, retention, and lifetime value are improving. Profitability is also moving higher as the company becomes a more pure-play franchisor, and management believes newer clinics are opening more efficiently and reaching breakeven much faster.
The main bear case is that consumer spending remains under pressure, which is still holding back new patient demand and average spend per month. Management lowered full-year system-wide sales guidance and expects the clinic count to end the year about 50 units below 2025, underscoring that the system is still being rationalized rather than expanding.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.8%
- Shares Outstanding
- 13.69M
- Float Shares
- 11.47M
of shares held by institutions
90 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bandera Partners LLC | 3.94M | 0 |
| Vanguard Group Inc | 1.00M | ▼ 43.46K |
| Skylands Capital, LLC | 946.04K | ▲ 50.47K |
| Jcp Investment Management, LLC | 593.91K | 0 |
| Vanguard Capital Management LLC | 349.76K | ▼ 207.29K |
| First Foundation Advisors | 341.15K | ▲ 6.29K |
| Blackrock, Inc. | 303.91K | ▲ 15.29K |
| Marshall Wace, Llp | 251.09K | ▲ 197.92K |
| Vanguard Portfolio Management LLC | 224.74K | 0 |
| Renaissance Technologies LLC | 210.28K | ▼ 9.20K |
| Dimensional Fund Advisors LP | 157.39K | ▲ 7.19K |
| Douglass Winthrop Advisors, LLC | 147.10K | 0 |
Held by 48 ETFs
Biggest fund positions in JYNT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 26 | JOBSON CHARLES E | buy | 44,963 |
| Nov 18, 26 | JOBSON CHARLES E | buy | 10,396 |
| Nov 17, 26 | JOBSON CHARLES E | buy | 1,614 |
| Nov 16, 26 | JOBSON CHARLES E | buy | 1,483 |
| Nov 10, 26 | JOBSON CHARLES E | buy | 2,825 |
| Nov 10, 26 | JOBSON CHARLES E | buy | 2,825 |
| Nov 9, 26 | JOBSON CHARLES E | buy | 236,116 |
| Nov 6, 26 | JOBSON CHARLES E | buy | 179 |
| Jun 10, 26 | Bowman Scott Justin | other | 1,392 |
| May 20, 26 | Pant Milind | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our JYNT coverage
Recent articles, reports, and earnings notes.
No research on JYNT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JYNT report →Beeline and TYTL to Host Joint Stakeholder Update Call on Merger Agreement with TYTL Corp.
globenewswire.com · Nov 20
Verlinvest Announces Commencement of Technical Tender Offer to Facilitate Buyout of Joint Venture Partner's Interest in Oatly Group AB
prnewswire.com · Nov 20
E-Power's Joint Venture Designated a National-Level “Little Giant” Enterprise by China's Ministry of Industry and Information Technology
globenewswire.com · Nov 20
BrenX Targets Europe's 1 Billion Euro Industrial Heat Auction Through Planned Joint Applications with Major Industrial Companies in Food, Chemicals and Tires
newsfilecorp.com · Nov 20
Gates to Acquire Nitta Interests in Five Asia-Pacific Markets, Concluding a Longstanding Joint Venture
prnewswire.com · Nov 19
AI Era Corp. Secures Exclusive U.S. Theatrical the Ufilm AI Creator Ecosystem License Through Joint Venture with CineCine
globenewswire.com · Nov 16
Desert Mountain Energy Signs Binding Letter of Intent for Kansas Natural Gas and Helium Joint Venture
thenewswire.com · Nov 16
Cosa Intersects Anomalous Radioactivity and Additional Prospective Geology at Darby Joint Venture with Denison Mines
newsfilecorp.com · Nov 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.